Skip to main content
. Author manuscript; available in PMC: 2010 Nov 1.
Published in final edited form as: Cancer Lett. 2009 May 12;284(2):157–164. doi: 10.1016/j.canlet.2009.04.016

Fig. 5.

Fig. 5

Knockdown of PF by siRNA decreases cell sensitivity to camptothecin. (A) Verification of PF expression by Western blot analysis. Whole cell lysate of Rh30 cells treated with NT siRNA or PF siRNA were analyzed by Western blotting with FKHR-specific antibody and anti β-actin antibody (as loading control). (B) Cell proliferation assay. After transfection with NT siRNA (control) or PF siRNA, cells were treated with 150 nM camptothecin for 48 h; cell viability was determined by the CellTiter-Glo® assay. Data represent 3 independent experiments, each performed in triplicate. Error bars indicate the standard error of the mean. Differences between PF siRNA and NT siRNA treatments in Rh30 cells was significant (p < 0.05) (*).